Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

The article concludes that hair loss is a common side effect of drugs treating skin cancer by blocking the hedgehog pathway, but treatment should continue, and more selective drugs might prevent this side effect.

New treatments targeting the Hedgehog pathway can help treat advanced skin cancer but may have side effects and their effectiveness in early stages is unknown.

Different tumor cells in one basal cell carcinoma can cause mixed treatment responses, suggesting personalized treatment is needed.

Reporter characteristics affect detection of hair loss from cancer therapy.

Reporter characteristics affect detection of hair loss from cancer therapy.

Vepdegestrant may become the first FDA-approved PROTAC degrader, marking a new era in drug development.

Targeted cancer therapies often cause skin reactions, so dermatologists must manage these effects.

The document concludes that side effects from Smoothened inhibitor drugs for skin cancer are reversible and can be managed with a team approach to maintain quality of life.

Hedgehog pathway inhibitors for advanced basal cell carcinoma can cause side effects, but managing them helps maintain treatment.

Vismodegib is effective for basal cell carcinoma but has severe side effects.

Vismodegib can cause muscle spasms, taste changes, hair loss, fatigue, weight loss, and possibly new issues like skin cancer, dehydration, and swallowing problems, needing close monitoring.

Personalized sonidegib dosing can effectively treat Gorlin-Goltz syndrome with fewer side effects.

Understanding drug interactions, side effects, and patient-specific factors is crucial for effective dermatological care.

Cancer treatments can cause skin-related side effects that may affect patient quality of life and require changes in treatment.

The new electrode improves long-term monitoring on hairy skin by reducing motion issues and is easy to use.

Enfortumab vedotin can cause skin issues, especially in older males, needing early monitoring.

Sonidegib and vismodegib have different side effects and reporting patterns.

N13-substituted evodiamine derivatives improved anticancer activity and solubility, showing promise for drug development.

Antiviral drugs, especially daclatasvir, may be a new treatment for a rare skin disease, improving survival and reducing symptoms in mice.

Iressa often causes skin issues like acne and dryness in lung cancer patients.

Ixekizumab is effective and safe for patients who did not improve with etanercept treatment for psoriasis.

XEDAR triggers a specific signaling pathway in cells.

Equisetum arvense extract in gels may enhance drug release for treatments.

ZD1839 (Iressa) causes skin and hair side effects, treatable with tretinoin cream and minocycline.

ZD1839 can cause skin issues like acne and hair changes.

The FDA did not approve a testosterone drug because of safety concerns.

The synthetic retinoid EC23 thickens skin and promotes hair growth more effectively and with a lower dose than natural retinoids.

VYN201 shows promise as a safe and effective treatment for non-segmental vitiligo.

A new mutation in the XEDAR gene might cause a rare skin condition called hypohidrotic ectodermal dysplasia.

Equisetum debile extracts may help with skin whitening, anti-wrinkle, and anti-hair loss treatments.